Last reviewed · How we verify
Beta Blockers Carvedilol Phosphate
Carvedilol phosphate is a non-selective beta-adrenergic receptor antagonist that blocks beta-1 and beta-2 receptors to reduce heart rate, blood pressure, and cardiac workload.
Carvedilol phosphate is a non-selective beta-adrenergic receptor antagonist that blocks beta-1 and beta-2 receptors to reduce heart rate, blood pressure, and cardiac workload. Used for Hypertension, Heart failure (systolic), Left ventricular dysfunction post-myocardial infarction.
At a glance
| Generic name | Beta Blockers Carvedilol Phosphate |
|---|---|
| Sponsor | Seoul National University Hospital |
| Drug class | Beta blocker (non-selective, with alpha-1 blocking activity) |
| Target | Beta-1 adrenergic receptor, Beta-2 adrenergic receptor, Alpha-1 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Carvedilol is a third-generation beta blocker with additional alpha-1 blocking properties, which provides vasodilatory effects beyond typical beta blockade. It reduces sympathetic nervous system activity on the heart and blood vessels, decreasing myocardial oxygen demand and improving cardiac efficiency. The phosphate salt formulation enhances solubility and bioavailability compared to the free base.
Approved indications
- Hypertension
- Heart failure (systolic)
- Left ventricular dysfunction post-myocardial infarction
- Angina pectoris
Common side effects
- Dizziness
- Fatigue
- Bradycardia
- Hypotension
- Hyperglycemia
- Bronchospasm
Key clinical trials
- Lisinopril or Coreg CR® in Reducing Side Effects in Women With Breast Cancer Receiving Trastuzumab (PHASE2)
- COREG MR Versus TOPROL-XL On The Lipid Profile Of Normolipidemic Or Mildly Dyslipidemic Patients With Hypertension (PHASE3)
- Efficacy of Coreg CR and Lisinopril on Markers for Cardiovascular Functional and Structural Disease (PHASE1, PHASE2)
- Effect of Beta-blocker on Cardioprotective Effect of Remote Ischemic Conditioning (PHASE4)
- A Phase I/II Clinical Study of SK&F-105517-D in Japanese Patients With Chronic Heart Failure (PHASE1)
- COREG MR Versus TOPROL-XL On Reduction Of Microalbuminuria In Patients With Hypertension And Microalbuminuria (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: